Nav: Home

Study identifies new potential target in glioblastoma

July 10, 2019

TORONTO, July 10, 2019 -- Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.

Research led by Toronto's St. Michael's Hospital and The Hospital for Sick Children (SickKids) suggests the protein ID1 is critical to tumour initiation and growth and also impacts the disease's response to chemotherapy. ID1 is a protein that keeps other genes from being activated or repressed by binding to their activators or inhibitors. In this work, scientists found that ID1 helps maintain cancer stem cells in glioblastoma, making them less susceptible to treatment.

"The field has postulated for years that cancer stem cells are a small population within the tumour but critical because they mediate treatment resistance and cancer resistance," said Dr. Sunit Das, a scientist at St. Michael's Keenan Research Centre for Biomedical Science and The Arthur and Sonia Labatt Brain Tumour Research Centre at SickKids. "We've now found proof of that speculation."

Researchers found that when they "turned off" the protein ID1 in lab models and human cells using CRISPR technology or a drug that is traditionally used to treat psychosis and Tourette's syndrome - pimozide - glioblastoma tumours slowed down. The team also found that turning off the protein altogether helped tumours become less resistant to chemotherapy.

Glioblastoma is an aggressive form of brain cancer, representing 15 per cent of all primary brain tumours, and is often difficult to treat. Therapy generally involves the combination of several approaches to control the disease, but there is currently no cure. The diagnoses of the late Tragically Hip singer Gord Downie and U.S. Sen. John McCain have raised the profile of glioblastoma in recent years.

"The average survival rate for glioblastoma is less than two years and we unfortunately don't have too many options to offer these patients," said Dr. Das, who is also a neurosurgeon at St. Michael's.

"Our findings suggest that we may be able to enhance the effectiveness of therapies we already have, such as chemotherapy, as opposed to taking many years to create entirely new therapies."

In lab models, researchers found that inhibiting ID1 slows the progression of tumours in glioblastoma, breast adenocarcinoma and melanoma. In human tissue, they found that the protein caused cells to be more resistant to chemotherapy treatment in glioblastoma. Turning off this protein using the medication pimozide increased overall survival and caused glioblastoma tumours to recur less frequently, progress less and grow more slowly.

"Targeting the protein with medication may present a novel and potentially promising strategy for patients with glioblastoma," Dr. Das said.

The next steps for this research, Dr. Das explained, are to look at the development of new inhibiting medications for ID1 and commence a trial to ensure that the targeting is effective.
-end-
About St. Michael's Hospital

St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 29 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

About Unity Health Toronto

Unity Health Toronto, comprised of Providence Healthcare, St. Joseph's Health Centre and St. Michael's Hospital, works to advance the health of everyone in our urban communities and beyond. Our health network serves patients, residents and clients across the full spectrum of care, spanning primary care, secondary community care, tertiary and quaternary care services to post-acute through rehabilitation, palliative care and long-term care, while investing in world-class research and education. For more information, visit http://www.unityhealth.to.

About The Hospital for Sick Children (SickKids)

The Hospital for Sick Children (SickKids) is recognized as one of the world's foremost paediatric health-care institutions and is Canada's leading centre dedicated to advancing children's health through the integration of patient care, research and education. Founded in 1875 and affiliated with the University of Toronto, SickKids is one of Canada's most research-intensive hospitals and has generated discoveries that have helped children globally. Its mission is to provide the best in complex and specialized family-centred care; pioneer scientific and clinical advancements; share expertise; foster an academic environment that nurtures health-care professionals; and champion an accessible, comprehensive and sustainable child health system. SickKids is a founding member of Kids Health Alliance, a network of partners working to create a high quality, consistent and coordinated approach to paediatric health care that is centred around children, youth and their families. SickKids is proud of its vision for Healthier Children. A Better World. For more information, please visit http://www.sickkids.ca.

Media Contact, St. Michael's Hospital

Michael Oliveira
oliveiram@smh.ca
416-864-5047

Media Contact, SickKids

Sasha Babakhanova
sasha.babakhanova@sickkids.ca
416-813-7910 ext. 228469

St. Michael's Hospital

Related Chemotherapy Articles:

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.
Male fertility after chemotherapy: New questions raised
Professor Delbès, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.
'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.
Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Chemotherapy or not?
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how 'smart' diagnostic-imaging machines identify cancers -- and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
Researchers use radiomics to predict who will benefit from chemotherapy
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study.
How drugs can minimize the side effects of chemotherapy
Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy.
More Chemotherapy News and Chemotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.